Cannabis Science Releases Forward-Looking Clinical Guidance for 2016; the Company Is Positioned to Expand Clinical Trials Into the New Year

COLORADO SPRINGS, CO--(Marketwired - Jan 5, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to release forward-looking guidance for 2016. With the pharmaceutical industry in closely targeted sights, Cannabis Science has started the new year healthier than any year prior.

The Company has placed heavy emphasis to accelerate its pharmaceutical drug development programs, as the industry is expected to reach $1.2 trillion globally by 2018. The Company's main goal here is to acquire national and international regulatory approval for its cannabis-based formulations, subsequently giving the Company substantial revenue growth considerations. The Company is focused on three main formal drug targets, proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Further to its expanded pharmaceutical drug development program with partner ImmunoClin (IMCL) out of Europe. The fully GMP compliant facilities are licensed and the Company is already working in the lab to realistically accomplish its aggressive goals. The expanded program is focused on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

In the State of California, Cannabis Science is seeing great success with initial production and testing of its Pure Decarboxylated CO2 Oil (PDCO) and CBD, Sativa, and Indica Capsule products during the last quarter of 2015. The capsules were debuted at The Emerald Cup, a cannabis-centric event attended by over 20,000 consumers and industry vendors. In 2016, product improvements will continue to be made and these products will be rolled out to a wider array of dispensaries. Marketing efforts for the capsule products will be ramped up in 2016, as the company's products are now completely viable and have received outstanding feedback from consumers to date.

To further cement its foothold in the substantial pharmaceutical drug development industry, the Company expects its IGXBIO, Genepro drug development program to be a major pharmaceutical win. Program specific details are expected to be announced in early 2016.

"2015 was a great year of growth for our Company. We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search," said company Director, President, Co-Founder & CEO, Raymond C. Dabney. "With that said, 2016 is looking to be an exciting year for Cannabis Science. We are kicking off the new year with new products already brought to market -- a huge head start over last year. We look forward to announcing all of our ground-breaking progress, step by step, along the way."

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.